Literature DB >> 7843183

Dissemination of cephalosporin-resistant Serratia marcescens strains producing a plasmidic SHV type beta-lactamase in Greek hospitals.

D Gianneli1, E Tzelepi, L S Tzouvelekis, A F Mentis, C Nikolopoulou.   

Abstract

The resistance to third generation cephalosporins in nine Serratia marcescens strains isolated in Greek hospitals was studied. Eight of the strains transferred resistance to Escherichia coli by means of large plasmids that encoded for an extended-spectrum beta-lactamase. Hybridization, isoelectric focusing and hydrolysis studies showed that the enzyme resembled the SHV-5 beta-lactamase. In the eight isolates that possessed the SHV type enzyme, cephalosporinase expression was inducible, whereas the remaining strain was a cephalosporinase hyperproducing strain. Introduction of a plasmid coding for the regulatory ampD gene in the latter strain eliminated beta-lactamase production and rendered the strain susceptible to cephalosporins.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7843183     DOI: 10.1007/bf02276063

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  14 in total

1.  Cloning of SHV-2, OHIO-1, and OXA-6 beta-lactamases and cloning and sequencing of SHV-1 beta-lactamase.

Authors:  J Mercier; R C Levesque
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

2.  Prevalence of a transferable SHV-5 type beta-lactamase in clinical isolates of Klebsiella pneumoniae and Escherichia coli in Greece.

Authors:  A C Vatopoulos; A Philippon; L S Tzouvelekis; Z Komninou; N J Legakis
Journal:  J Antimicrob Chemother       Date:  1990-11       Impact factor: 5.790

3.  Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns.

Authors:  V Jarlier; M H Nicolas; G Fournier; A Philippon
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

4.  Effects of beta-lactamase from gram-negative organisms on cephalosporins and penicillins.

Authors:  C H O'Callaghan; P W Muggleton; G W Ross
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1968

5.  Emergence of resistance to beta-lactams, aminoglycosides, and quinolones during combination therapy for infection due to Serratia marcescens.

Authors:  C C Sanders; C Watanakunakorn
Journal:  J Infect Dis       Date:  1986-03       Impact factor: 5.226

6.  Characterization of plasmids and plasmid-associated determinants of Yersinia enterocolitica pathogenesis.

Authors:  D A Portnoy; S L Moseley; S Falkow
Journal:  Infect Immun       Date:  1981-02       Impact factor: 3.441

7.  High prevalence of stably derepressed class-I beta-lactamase expression in multiresistant clinical isolates of Enterobacter cloacae from Greek hospitals.

Authors:  E Tzelepi; L S Tzouvelekis; A C Vatopoulos; A F Mentis; A Tsakris; N J Legakis
Journal:  J Med Microbiol       Date:  1992-08       Impact factor: 2.472

8.  Identification of a novel plasmid-mediated beta-lactamase with chromosomal cephalosporinase characteristics from Klebsiella pneumoniae.

Authors:  L S Tzouvelekis; E Tzelepi; A F Mentis; A Tsakris
Journal:  J Antimicrob Chemother       Date:  1993-05       Impact factor: 5.790

9.  Comparison of endemic and epidemic nosocomial infections.

Authors:  W E Stamm; R A Weinstein; R E Dixon
Journal:  Am J Med       Date:  1981-02       Impact factor: 4.965

10.  Inducible cephalosporinase production in clinical isolates of Enterobacter cloacae is controlled by a regulatory gene that has been deleted from Escherichia coli.

Authors:  N Honoré; M H Nicolas; S T Cole
Journal:  EMBO J       Date:  1986-12-20       Impact factor: 11.598

View more
  9 in total

1.  Comparison of screening methods for detection of extended-spectrum beta-lactamases and their prevalence among blood isolates of Escherichia coli and Klebsiella spp. in a Belgian teaching hospital.

Authors:  E Vercauteren; P Descheemaeker; M Ieven; C C Sanders; H Goossens
Journal:  J Clin Microbiol       Date:  1997-09       Impact factor: 5.948

2.  Detection of extended-spectrum beta-lactamases in clinical isolates of Enterobacter cloacae and Enterobacter aerogenes.

Authors:  E Tzelepi; P Giakkoupi; D Sofianou; V Loukova; A Kemeroglou; A Tsakris
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

3.  Evaluation of a novel kit for the rapid detection of extended-spectrum beta-lactamases.

Authors:  R Colodner; B Reznik; V Gal; H Yamazaki; H Hanaki; R Kubo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-01       Impact factor: 3.267

4.  In vitro activity of cefpirome against selected clinical enterobacterial isolates with beta-lactamase-mediated resistance.

Authors:  L S Tzouvelekis; E Tzelepi; A F Mentis; N J Legakis
Journal:  Infection       Date:  1995 Nov-Dec       Impact factor: 3.553

5.  Repeated epidemics caused by extended-spectrum beta-lactamase-producing Serratia marcescens strains.

Authors:  F Luzzaro; M Perilli; R Migliavacca; G Lombardi; P Micheletti; A Agodi; S Stefani; G Amicosante; L Pagani
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-09       Impact factor: 3.267

6.  Survey and molecular genetics of SHV beta-lactamases in Enterobacteriaceae in Switzerland: two novel enzymes, SHV-11 and SHV-12.

Authors:  M T Nüesch-Inderbinen; F H Kayser; H Hächler
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

7.  Rapid discriminatory detection of genes coding for SHV beta-lactamases by ligase chain reaction.

Authors:  J Kim; H J Lee
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

Review 8.  beta-Lactamases in laboratory and clinical resistance.

Authors:  D M Livermore
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

9.  Nosocomial outbreak of extended-spectrum beta-lactamase SHV-5-producing isolates of Pseudomonas aeruginosa in Athens, Greece.

Authors:  Laurent Poirel; Evangelia Lebessi; Marisa Castro; Cindy Fèvre; Maria Foustoukou; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.